ÂÜÀòÂÒÂ×

Paul Wolfrom is an accomplished finance professional with extensive experience in the biopharmaceutical and financial sectors. As Co-Founder and CFO of LimmaTech Biologics AG since July 2015, Paul has been instrumental in advancing innovative vaccine technologies to address antimicrobial resistance. Previously serving as CFO at Glycovaxyn AG and Source Capital AG, Paul has demonstrated expertise in managing financial operations within clinical stage and trading firms. Prior to these roles, Paul held significant positions at Investors Guaranty, CounterpartyLink, SEI Capital AG, and SEI Investments Company, contributing to private equity, strategic planning, and financial management. Paul possesses an MBA in Finance from Villanova University and a BS in Finance from La Salle University, complemented by further education at the Swiss Finance Institute.